Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Waitlist-Control Trial of Bumetanide in Children with Autism
2021-003851-41Phase 2Active
- Sponsor
- Gillberg Neuropsychiatry Centre
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bumetanide in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Gillberg Neuropsychiatry Centre. Primary endpoints: Parental Satisfaction Survey (PASS) score – parent ratings at 3 months and Parental Satisfaction Survey (PASS) score – parent ratings at 6 months. Started Sep 2021; status: active.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2021-003851-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003851-41.